The ASGR1 Knockout HGC-27 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout population derived from the HGC-27 human gastric adenocarcinoma cell line. This product features a targeted disruption of the ASGR1 gene, encoding the major asialoglycoprotein receptor subunit. The polyclonal format provides a heterogeneous pool of mutant alleles, ideal for loss-of-function studies without clonal bias. These cells enable investigation of ASGR1-dependent pathways in an epithelial gastric cancer context.
HGC-27 is a poorly differentiated gastric adenocarcinoma cell line originating from a lymph node metastasis in a 43-year-old Japanese male. The cells display epithelial morphology and are extensively used to study gastric cancer biology, including metastasis, invasion, and drug response mechanisms. The ASGR1 disruption in this model facilitates analysis of glycoprotein receptor function in a metastatic gastric carcinoma background.
ASGR1 encodes a C-type lectin receptor that, together with ASGR2, mediates clathrin-dependent endocytosis of desialylated glycoproteins. Ligand binding triggers recruitment of the AP-2 adaptor complex and Eps15, leading to internalization via clathrin-coated pits. Internalized complexes are transported to early endosomes (EEA1-positive) and ultimately to lysosomes for degradation by cathepsins. ASGR1 expression is transcriptionally regulated by HNF4??, HNF1??, FOXA2, and the glucocorticoid receptor. Disruption of ASGR1 abolishes this endocytic clearance pathway, affecting glycoprotein turnover and potentially altering cell surface glycosylation patterns.
In gastric cancer, aberrant glycosylation is common, and ASGR1 may influence cell adhesion, migration, and proliferation by modulating glycoprotein profiles. The knockout in HGC-27 cells allows direct assessment of these roles, providing a model to explore how loss of the asialoglycoprotein receptor impacts metastatic behavior. This tool is also useful for screening glycoconjugate-based therapeutics targeting the ASGR pathway.
Key applications include ligand-uptake endocytosis assays, Western blotting for ASGR1-ASGR2 complex detection, and Transwell migration/invasion studies. The cells are compatible with flow cytometry, immunofluorescence, RT-qPCR, and apoptosis assays. The polyclonal knockout pool supports pooled screens and bulk functional genomics experiments. For technical inquiries, please contact Ascent Research.
